1 / 7

Dr. Peter Kurz Agilent Technologies International Sàrl Morges 25 April 2005

Roles and Perspectives in Science Collaboration – the view of the high-tech industry. Dr. Peter Kurz Agilent Technologies International Sàrl Morges 25 April 2005. November 1, 1999. Test and Measurement. Automated Test. Life Sciences and Chemical Analysis. Semiconductor Products. $2.9B.

loyal
Download Presentation

Dr. Peter Kurz Agilent Technologies International Sàrl Morges 25 April 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Roles and Perspectives in Science Collaboration – the view of the high-tech industry Dr. Peter KurzAgilent Technologies International SàrlMorges25 April 2005

  2. November 1, 1999

  3. Test andMeasurement Automated Test Life Sciences andChemical Analysis SemiconductorProducts $2.9B $2.0B $0.9B $1.3B Agilent Revenue – FY04 Agilent Laboratories

  4. Agilent’s university collaborationsBasic observations & shifts in direction • More basic research and less applied research @ universities, due to internal shifts in Agilent. Sometimes of philanthropic nature (e.g., funding a professorship). • Not much contract research (of the type „Run this project for us“), rather funding of research conducted at the university, provided Agilent has an interest in the results. Exception: projects where only the university has expertise • Some research funded by EU or local governments • Acquisition of university spin-offs or university IP

  5. Agilent’s university collaborationsRecent Issues • Universitites under too much pressure to commercialize & do not understand a) the investments required for product development, b) the limits of IP protection and c) the basis of profit calculation. E.g., a 20% royalty on a lab-status technology is usually not an option, unless there are special leverages. Examples: • Equity investment in spin-off failed because there were only 3 recently filed patent applications and one of the professors held unspecified rights in them • Expected royalty rate was so excessive that Agilent decided not to fund a project, but rather hire a scientist from the university. Now, government money could not be assigned

  6. Agilent’s university collaborationsConflicts • In our experience, conflicts arise rather during the negotiation of the contract, than during execution. • There is one essential bottleneck that has a name: University Legal Departments. (Slow in response, no power to compromise, ...)One particular issue with the revision of § 42 Inventor Code in Germany: the professor is no longer the owner of his/her inventions. => 3 or 4 parties to agree (funding company, university, professor, student if any). Agilent has split up the agreements into 3 for that purpose.

  7. Thank you for your attention !

More Related